244 related articles for article (PubMed ID: 28966234)
1. Emerging and Diverse Functions of the EphA2 Noncanonical Pathway in Cancer Progression.
Zhou Y; Sakurai H
Biol Pharm Bull; 2017; 40(10):1616-1624. PubMed ID: 28966234
[TBL] [Abstract][Full Text] [Related]
2. Crucial roles of RSK in cell motility by catalysing serine phosphorylation of EphA2.
Zhou Y; Yamada N; Tanaka T; Hori T; Yokoyama S; Hayakawa Y; Yano S; Fukuoka J; Koizumi K; Saiki I; Sakurai H
Nat Commun; 2015 Jul; 6():7679. PubMed ID: 26158630
[TBL] [Abstract][Full Text] [Related]
3. Protein kinase A can block EphA2 receptor-mediated cell repulsion by increasing EphA2 S897 phosphorylation.
Barquilla A; Lamberto I; Noberini R; Heynen-Genel S; Brill LM; Pasquale EB
Mol Biol Cell; 2016 Sep; 27(17):2757-70. PubMed ID: 27385333
[TBL] [Abstract][Full Text] [Related]
4. Cellular stress induces non-canonical activation of the receptor tyrosine kinase EphA2 through the p38-MK2-RSK signaling pathway.
Zhou Y; Oki R; Tanaka A; Song L; Takashima A; Hamada N; Yokoyama S; Yano S; Sakurai H
J Biol Chem; 2023 May; 299(5):104699. PubMed ID: 37059179
[TBL] [Abstract][Full Text] [Related]
5. Targeting EphA2: a promising strategy to overcome chemoresistance and drug resistance in cancer.
Veiga RN; de Azevedo ALK; de Oliveira JC; Gradia DF
J Mol Med (Berl); 2024 Apr; 102(4):479-493. PubMed ID: 38393661
[TBL] [Abstract][Full Text] [Related]
6. Crosstalk of the EphA2 receptor with a serine/threonine phosphatase suppresses the Akt-mTORC1 pathway in cancer cells.
Yang NY; Fernandez C; Richter M; Xiao Z; Valencia F; Tice DA; Pasquale EB
Cell Signal; 2011 Jan; 23(1):201-12. PubMed ID: 20837138
[TBL] [Abstract][Full Text] [Related]
7. [Non-canonical Activation of Receptor Tyrosine Kinases in Cancer Progression].
Sakurai H
Yakugaku Zasshi; 2017; 137(2):141-144. PubMed ID: 28154322
[TBL] [Abstract][Full Text] [Related]
8. The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting.
Wykosky J; Debinski W
Mol Cancer Res; 2008 Dec; 6(12):1795-806. PubMed ID: 19074825
[TBL] [Abstract][Full Text] [Related]
9. A kinase-dependent role for EphA2 receptor in promoting tumor growth and metastasis.
Fang WB; Brantley-Sieders DM; Parker MA; Reith AD; Chen J
Oncogene; 2005 Nov; 24(53):7859-68. PubMed ID: 16103880
[TBL] [Abstract][Full Text] [Related]
10. Tyrosine kinase activity of EphA2 promotes its S897 phosphorylation and glioblastoma cell proliferation.
Hamaoka Y; Negishi M; Katoh H
Biochem Biophys Res Commun; 2018 May; 499(4):920-926. PubMed ID: 29626472
[TBL] [Abstract][Full Text] [Related]
11. Phosphoproteomic profiling of NSCLC cells reveals that ephrin B3 regulates pro-survival signaling through Akt1-mediated phosphorylation of the EphA2 receptor.
Ståhl S; Branca RM; Efazat G; Ruzzene M; Zhivotovsky B; Lewensohn R; Viktorsson K; Lehtiö J
J Proteome Res; 2011 May; 10(5):2566-78. PubMed ID: 21413766
[TBL] [Abstract][Full Text] [Related]
12. Erythropoietin-Producing Hepatoma Receptor Tyrosine Kinase A2 Modulation Associates with Protective Effect of Prone Position in Ventilator-induced Lung Injury.
Park BH; Shin MH; Douglas IS; Chung KS; Song JH; Kim SY; Kim EY; Jung JY; Kang YA; Chang J; Kim YS; Park MS
Am J Respir Cell Mol Biol; 2018 Apr; 58(4):519-529. PubMed ID: 29216437
[TBL] [Abstract][Full Text] [Related]
13. Protein kinase C phosphorylates the EphA2 receptor on serine 892 in the regulatory linker connecting the kinase and SAM domains.
Gehring MP; Pasquale EB
Cell Signal; 2020 Sep; 73():109668. PubMed ID: 32413552
[TBL] [Abstract][Full Text] [Related]
14. Overexpression and functional alterations of the EphA2 tyrosine kinase in cancer.
Kinch MS; Carles-Kinch K
Clin Exp Metastasis; 2003; 20(1):59-68. PubMed ID: 12650608
[TBL] [Abstract][Full Text] [Related]
15. EphA2-dependent molecular targeting therapy for malignant tumors.
Biao-xue R; Xi-guang C; Shuan-ying Y; Wei L; Zong-juan M
Curr Cancer Drug Targets; 2011 Nov; 11(9):1082-97. PubMed ID: 21933105
[TBL] [Abstract][Full Text] [Related]
16. EphA2 Receptor Unliganded Dimers Suppress EphA2 Pro-tumorigenic Signaling.
Singh DR; Ahmed F; King C; Gupta N; Salotto M; Pasquale EB; Hristova K
J Biol Chem; 2015 Nov; 290(45):27271-27279. PubMed ID: 26363067
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of EPHA2 receptor destabilizes adherens junctions via a RhoA-dependent mechanism.
Fang WB; Ireton RC; Zhuang G; Takahashi T; Reynolds A; Chen J
J Cell Sci; 2008 Feb; 121(Pt 3):358-68. PubMed ID: 18198190
[TBL] [Abstract][Full Text] [Related]
18. Progranulin/EphA2 axis: A novel oncogenic mechanism in bladder cancer.
Buraschi S; Neill T; Xu SQ; Palladino C; Belfiore A; Iozzo RV; Morrione A
Matrix Biol; 2020 Nov; 93():10-24. PubMed ID: 32417448
[TBL] [Abstract][Full Text] [Related]
19. EphA2 is a key effector of the MEK/ERK/RSK pathway regulating glioblastoma cell proliferation.
Hamaoka Y; Negishi M; Katoh H
Cell Signal; 2016 Aug; 28(8):937-45. PubMed ID: 27132626
[TBL] [Abstract][Full Text] [Related]
20. Proteolysis of EphA2 Converts It from a Tumor Suppressor to an Oncoprotein.
Koshikawa N; Hoshino D; Taniguchi H; Minegishi T; Tomari T; Nam SO; Aoki M; Sueta T; Nakagawa T; Miyamoto S; Nabeshima K; Weaver AM; Seiki M
Cancer Res; 2015 Aug; 75(16):3327-39. PubMed ID: 26130649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
